ATEC vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals significant concerns with a Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a full solvency assessment. Despite strong revenue growth of 30.4% and a bullish analyst recommendation (strong_buy), the company is unprofitable with a -21.29% profit margin and an alarming ROE of -540.41%. High valuation multiples, including a Price/Book of 200.26 and Forward P/E of 79.16, are not supported by current earnings or cash flow, while insider selling of $55.28M in the last six months signals strong bearish sentiment from management. Technical trend is bearish, and recent price performance shows a sharp 1-month decline of -24.8%, suggesting weakening momentum.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ATEC vs MRK: Head-to-Head Comparison
This page compares Alphatec Holdings, Inc. (ATEC) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.